ERBB2 and breast cancer: The triple-negative subtype of breast cancer (TNBC) accounts for 15–20% of cases (2, 3) and is characterized by an absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression (3–5).